Jeffrey T L Smith, the EVP & Chief Medical Officer of $ZYME, sold 10,538 shares of the company on 01-05-2026 for an estimated $264,471. We received data on the trade from a recent SEC filing. This was a sale of approximately 36.5% of their shares of this class of stock. Following this trade, they now own 18,352 shares of this class of $ZYME stock.
$ZYME Insider Trading Activity
$ZYME insiders have traded $ZYME stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $ZYME stock by insiders over the last 6 months:
- KENNETH GALBRAITH (Chair & CEO) has made 0 purchases and 3 sales selling 101,871 shares for an estimated $2,648,151.
- PAUL ANDREW MOORE (Chief Scientific Officer) has made 0 purchases and 2 sales selling 20,110 shares for an estimated $504,698.
- JEFFREY T L SMITH (EVP & Chief Medical Officer) sold 10,538 shares for an estimated $264,471
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ZYME Hedge Fund Activity
We have seen 88 institutional investors add shares of $ZYME stock to their portfolio, and 85 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. removed 2,039,656 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $34,837,324
- MILLENNIUM MANAGEMENT LLC added 988,711 shares (+851.6%) to their portfolio in Q3 2025, for an estimated $16,887,183
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 961,413 shares (+39.1%) to their portfolio in Q3 2025, for an estimated $16,420,934
- ASSENAGON ASSET MANAGEMENT S.A. added 833,994 shares (+169.2%) to their portfolio in Q3 2025, for an estimated $14,244,617
- PERCEPTIVE ADVISORS LLC added 815,389 shares (+63.9%) to their portfolio in Q3 2025, for an estimated $13,926,844
- VESTAL POINT CAPITAL, LP added 615,000 shares (+53.5%) to their portfolio in Q3 2025, for an estimated $10,504,199
- PROSIGHT MANAGEMENT, LP removed 560,293 shares (-42.8%) from their portfolio in Q3 2025, for an estimated $9,569,804
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ZYME Revenue
$ZYME had revenues of $27.6M in Q3 2025. This is an increase of 72.59% from the same period in the prior year.
You can track ZYME financials on Quiver Quantitative's ZYME stock page.
$ZYME Analyst Ratings
Wall Street analysts have issued reports on $ZYME in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Truist Securities issued a "Buy" rating on 12/17/2025
- B. Riley Securities issued a "Buy" rating on 11/21/2025
- Stifel issued a "Buy" rating on 11/19/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/18/2025
- Citigroup issued a "Buy" rating on 08/11/2025
To track analyst ratings and price targets for $ZYME, check out Quiver Quantitative's $ZYME forecast page.
$ZYME Price Targets
Multiple analysts have issued price targets for $ZYME recently. We have seen 8 analysts offer price targets for $ZYME in the last 6 months, with a median target of $32.5.
Here are some recent targets:
- Asthika Goonewardene from Truist Securities set a target price of $40.0 on 12/17/2025
- Eva Fortea Verdejo from Wells Fargo set a target price of $33.0 on 12/12/2025
- Reni J. Benjamin from Citizens set a target price of $32.0 on 12/03/2025
- Mayank Mamtani from B. Riley Securities set a target price of $40.0 on 11/21/2025
- Stephen Willey from Stifel set a target price of $40.0 on 11/19/2025
- Robert Burns from HC Wainwright & Co. set a target price of $32.0 on 11/18/2025
- Brian Cheng from JP Morgan set a target price of $23.0 on 10/16/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
